PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29553450-17	2018	However, more patients received SAMA than SABA, although SABA is more effective and therefore the first-line treatment for COPD exacerbation.	3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole	57-61	COPD	Homo sapiens	123-127	
25130680-1	2014	BACKGROUND: A simple rule based on short-acting inhaled beta2-agonist (SABA) use could identify patients with chronic obstructive pulmonary disease (COPD) at increased risk of exacerbations and signal the need for maintenance therapy change, similar to asthma "Rules of Two( )".	3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole	71-75	COPD	Homo sapiens	149-153	
25130680-9	2014	CONCLUSION: Patients with COPD using >=1.5 SABA doses/day were at increased risk of exacerbations.	3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole	46-50	COPD	Homo sapiens	26-30